Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine

An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroi...

Descripción completa

Detalles Bibliográficos
Autor principal: Pavenski, Katerina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459176/
https://www.ncbi.nlm.nih.gov/pubmed/34568744
http://dx.doi.org/10.1055/s-0041-1732342
_version_ 1784571465743466496
author Pavenski, Katerina
author_facet Pavenski, Katerina
author_sort Pavenski, Katerina
collection PubMed
description An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination.
format Online
Article
Text
id pubmed-8459176
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-84591762021-09-24 Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine Pavenski, Katerina TH Open An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination. Georg Thieme Verlag KG 2021-08-09 /pmc/articles/PMC8459176/ /pubmed/34568744 http://dx.doi.org/10.1055/s-0041-1732342 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pavenski, Katerina
Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
title Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
title_full Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
title_fullStr Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
title_full_unstemmed Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
title_short Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
title_sort relapse of immune thrombotic thrombocytopenic purpura following vaccination with covid19 mrna vaccine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459176/
https://www.ncbi.nlm.nih.gov/pubmed/34568744
http://dx.doi.org/10.1055/s-0041-1732342
work_keys_str_mv AT pavenskikaterina relapseofimmunethromboticthrombocytopenicpurpurafollowingvaccinationwithcovid19mrnavaccine

Ejemplares similares